RxDoctor Payments Data

Joseph Cardenas, MD

Cardiovascular Disease · Yuma, AZNPI 1568432193

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $17,378 of the $21,127 with a category attached, or 82.3%. 21 manufacturers reported payments, led by Endologix LLC at 34.3% of the total. Reporting peaked in 2021 at $9,077 and has fallen 94.6% since, to $493 in 2025.

$21,127in general payments, 2019–2025

Across 87 payments — averaging $242.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endologix LLC$7K
  • Cordis US CORP.$6K
  • Cardinal Health 200 LLC$5K
  • Shockwave Medical, Inc$569
  • Medtronic$297
  • Abbott$289
  • plus $1K from 15 others
$283,515in research payments, 2019–2025

Across 151 payments — averaging $1877.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Philips North America LLC$109K
  • Intact Vascular, Inc.$81K
  • Surmodics, Inc.$67K
  • Boston Scientific$21K
  • Cordis Corporation$6K

What the payments were for

  • Consulting fees$17,37882%
  • Travel & lodging$5092%
  • Food & beverage$3,24015%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,127 in reported general payments places this provider in the 85th percentile of 423 cardiovascular disease providers in Arizona.

See all cardiovascular disease providers in Arizona

Medicare billing

Part B allowed, 2024
$302,405
Medicare patients
449
Services billed
1,726

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban30$23,976
EntrestoSacubitril/Valsartan12$22,371
ClopidogrelClopidogrel Bisulfate316$4,665
Isosorbide Dinitrate60$2,393
Atorvastatin Calcium116$1,374
Carvedilol115$1,023
Metoprolol Succinate49$927
Nitroglycerin59$658
Isosorbide Mononitrate ErIsosorbide Mononitrate24$540
Rosuvastatin Calcium25$519
Losartan Potassium34$429
Potassium Chloride17$405
Metoprolol Tartrate72$399
Pravastatin Sodium24$340
Furosemide56$338

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Yuma

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →